PRAMOMOLECULAR GmbH

"PRAMO" means "ferry" in Esperanto. Based on the covalent, lipid-based "ferry molecules", PRAMOMOLECULAR can transfect in vivo tissue cells of lungs, heart and pancreas with therapeutic oligonucleotides such as siRNAs or antisense DNAs.

PRMOMOLECULAR is thus developing "self-delivering siRNA", a highly innovative class of drugs that can efficiently downregulate disease-causing proteins, e.g. cancer or metabolic proteins, in the target organs and is also licensing out the delivery technology for selected applications. Initial targets include NSCLC, PDAC, CC and heart failure."